myla capellan

[有好信博｜『体力がすべて』 @AriyoshiMd]

GLP-1薬（マンジャロなど）を中止すると、死亡リスクが約5倍？

イタリアの2型糖尿病患者約8万人を対象とした研究。GLP-1薬を中止した人は、継続した人と比べて、

・心筋梗塞・脳卒中・全死亡の複合指標：約2倍
・全死亡：約4.7倍

ただし、薬をやめたことでリスクが増えたのか、薬による保護効果が失われたのかは別の問題。

別の米国約33万人の研究では、心筋梗塞・脳卒中・全死亡の3年間の発生率は、

・GLP-1薬を継続：16.9%
・GLP-1薬を中止：19.9%
・別の糖尿病薬（SU薬）を開始：20.7%

つまり、中止した人のリスクは、GLP-1薬を継続した人より高かったものの、別の糖尿病薬で治療した人とほぼ同程度。

これは、GLP-1薬の中止が新たな害をもたらすというより、服用中に得られていた心血管保護効果が失われる可能性を示唆

＊観察研究

[EASO @EASOobesity]

The Fact Sheet developed by @ESPENorg and @EASOobesity on the nutritional risks of obesity management medications is now available to download!

Thanks to the 800+ colleagues who joined our webinar yesterday!

https://t.co/pGGewnVHpF

[Michael Morelli @morellifit]

This new tirzepatide study is eye-opening.

120 adults took the drug for 40 weeks, and half of them also lifted weights 3x a week. Both groups lost about 50 lbs.

But when they tested strength, the two groups looked nothing alike.

Here's the breakdown: (1/11)

[Scott Isaacs @scottisaacsmd]

Dysfunctional visceral fat activates metabolic, hormonal, and inflammatory pathways that damage the heart and blood vessels. Treating obesity addresses a key driver of cardiovascular disease.
https://t.co/Vijg6bPnxf

[Updates in Medicine @medic_updates]

Acute pancreatitis in 2026: diagnose, classify severity and reassess fluids. Persistent organ failure >48 h defines severe disease; deterioration needs earlier escalation. (1/3)

2026 iLATAM-AP guideline:
https://t.co/gK0ULXDw1o

[Saúl Sánchez @SaulNutri]

🚨 ¿Qué suplementos funcionan realmente para reducir la resistencia a la insulina y la inflamación en personas con sobrepeso u obesidad?

Un nuevo metaanálisis de 59 ensayos clínicos y 3263 participantes ha comparado 4 suplementos muy populares.🧵👇

[Jesse Morse, M.D. @DrJesseMorse]

Some of these new Retatrutide numbers are crazy impressive from the TRIUMPH-1 study:

70% reduction in knee pain score (‼️)
60% reduction in sleep apnea episodes
8-12 mm Hg drop in systolic BP
34-41% drop in triglycerides
15-20% drop in LDL
58-64% drop in inflammation 🤯
88-96% return to normal blood sugar 👏🏼
Massive positive impact on quality of life

Retatrutide is a CHEAT CODE.

It’s like 5 peptides in 1.

…and there’s more ⬇️

[Walter Suárez Carmona @a_fisiolog57853]

¿QUIÉN DEBERÍA PRESCRIBIR LA FARMACOLOGÍA PARA LA OBESIDAD?

¡¡¡A leer, zagales!!!

Link en mi bio

o

https://t.co/3Bo2WIJYPi

[AACE @TheAACE]

The AACE Patient Journey of Diabetes Technology outlines the many devices and tools that can help people with diabetes track their blood sugar, take their medication, and more. Point your patients to our video https://t.co/ZggXaW1MJo for a quick explainer on this useful resource.

[Euro J Endocrinology @EJEndo]

Subtype- and treatment-based analysis of calcium dynamics in primary aldosteronism by Toshifumi Nakamura et al

EJE Volume 194, Issue 2, February 2026
Open access 👉 https://t.co/wVjN1p63lE

#endocrinology #PrimaryAldosteronism #parathyroid #calcium #adrenalectomy

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

#PituitaryTumors may disrupt immune balance beyond their effects on hormones.

Researchers found that surgery helped normalize altered circulating immune-cell proportions, while blood immune signatures showed potential for distinguishing tumor subtypes.

#STTT #OpenAccess: https://t.co/B5ZkcLx24w

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

New—Who should prescribe obesity management medications? An IFSO position statement https://t.co/9kITPqghqR
#obesity
#FREE to read with registration (also FREE)

[Nutrition Science @NutrioSci]

Mediterranean diet and cancer risk: Current understanding and epidemiological evidence

Open Access
https://t.co/S5zLPvs5y6

#TIC2026 #nutrition #meded #medx

[Cristina Tejera @cristinatejerap]

Nuevo en @CircAHA AHA, pediatras (AAP), ginecólogos (ACOG) y medicina maternofetal (SMFM) firman juntos la primera guía por etapas vitales de la mujer. Cuatro fases (perimenarquia, ciclos ovulatorios, perimenopausia y posmenopausia) y el embarazo como prueba de esfuerzo que destapa el riesgo.

🔑menarquia antes de los 10 años, menopausia antes de los 45, PMOS (el antiguo SOP) y las complicaciones del embarazo: potenciadores de riesgo CV

🔑 Se aconseja también cribar depresión, ansiedad y TCA en todas las etapas

https://t.co/cg9OJbSWVo

[EASD @EASDnews]

❓Can #CGM detect beta cell dysfunction before glucose levels rise?
A new study in @DiabetologiaJnl by Marchiori et al. suggests that CGM-derived measures could help monitor beta cell function in preclinical #T1D.
Read more👉https://t.co/pbDumXBqBI

[AACE @TheAACE]

Endocrine Practice Highlight: This analysis, leveraging the safety data from ONWARDS 1-6, shows that the overall safety profiles of insulin icodec (icodec) and currently used daily basal insulins, including insulin degludec and insulin glargine, are comparable in people with type 2 diabetes or type 1 diabetes. Read more: https://t.co/p876Pfe8Eo

@vtangpricha

[AACE @TheAACE]

Endocrine Practice Highlight: Long-Term Antithyroid Drug Therapy in the Management of Graves’ Hyperthyroidism: An Updated Narrative Review

Findings showed that patient priorities, efficacy and safety, and higher remission rates could be achieved with long-term (more than) 5 years of antithyroid drug treatment, as compared to other treatment modalities.

Read more: https://t.co/IYh4uMQgos

@vtangpricha

[EJPC Editor-in-Chief @EJPCEiC]

🫀 From plaque formation to carotid stenosis: does lipoprotein(a) play a role?
Elevated Lp(a) (≥50 mg/dL) to both plaque development and progression to significant carotid stenosis, highlighting its relevance across the atherosclerotic continuum.
🔗 https://t.co/u4aK6EHCaC

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

New—The development of #obesity #pharmacotherapy: from early challenges and setbacks to recognition by WHO https://t.co/nsh6utV5Xh
#obesity

[Scott Isaacs @scottisaacsmd]

Phase 3 results from #retatrutide in TRIUMPH-1-OSA and TRIUMPH-2-OSA demonstrate significant reductions in #OSA, with AHI reductions of up to 34.3 events/hour and weight loss of up to 22.2% in patients without diabetes and 18.5% in those with type 2 diabetes.
https://t.co/nxKYlTXhWQ